Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2474
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab ; volume:16 ; number:1 ; day:24 ; month:7 ; year:2015 ; pages:1-8 ; date:12.2015
BMC musculoskeletal disorders ; 16, Heft 1 (24.7.2015), 1-8, 12.2015
- Creator
-
Lorenzin, Mariagrazia
- Contributor
-
Ortolan, Augusta
Frallonardo, Paola
Oliviero, Francesca
Punzi, Leonardo
Ramonda, Roberta
SpringerLink (Online service)
- DOI
-
10.1186/s12891-015-0620-4
- URN
-
urn:nbn:de:1111-2016110519312
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lorenzin, Mariagrazia
- Ortolan, Augusta
- Frallonardo, Paola
- Oliviero, Francesca
- Punzi, Leonardo
- Ramonda, Roberta
- SpringerLink (Online service)
Other Objects (12)
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Body mass index influences the response to infliximab in ankylosing spondylitis
Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
A case study: consequences of ANTI-TNFα therapy and foot ulcerations. A patient with Ankylosing Spondylitis (AS) treated with Infliximab
Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Andersson lesion in ankylosing spondylitis
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
T cell responses to putative antigens and downregulation of cytokineproduction by infliximab in ankylosing spondylitis patients
Incidence and predictors of morphometric vertebral fractures in patients with ankylosing spondylitis
T-cell response to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
T-cell responses to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Body mass index influences the response to infliximab in ankylosing spondylitis
Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
A case study: consequences of ANTI-TNFα therapy and foot ulcerations. A patient with Ankylosing Spondylitis (AS) treated with Infliximab
Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Andersson lesion in ankylosing spondylitis
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
T cell responses to putative antigens and downregulation of cytokineproduction by infliximab in ankylosing spondylitis patients
Incidence and predictors of morphometric vertebral fractures in patients with ankylosing spondylitis
T-cell response to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
T-cell responses to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Body mass index influences the response to infliximab in ankylosing spondylitis
Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
A case study: consequences of ANTI-TNFα therapy and foot ulcerations. A patient with Ankylosing Spondylitis (AS) treated with Infliximab
Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Andersson lesion in ankylosing spondylitis
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
T cell responses to putative antigens and downregulation of cytokineproduction by infliximab in ankylosing spondylitis patients
Incidence and predictors of morphometric vertebral fractures in patients with ankylosing spondylitis
T-cell response to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients